{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Esophageal+Cancer&page=6", "query": { "condition": "Stage IV Esophageal Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 172, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Esophageal+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Esophageal+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:29:07.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Brain and Central Nervous System Tumors", "Breast Cancer", "Esophageal Cancer", "Extragonadal Germ Cell Tumor", "Gastric Cancer", "Lung Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313599" }, { "nct_id": "NCT00006081", "title": "Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Bryostatin-1", "type": "DRUG" }, { "name": "Paclitaxel (Taxol)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2000-06", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006081" }, { "nct_id": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2025-07-30", "completion_date": "2032-01-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780111" }, { "nct_id": "NCT02381561", "title": "Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Bile Duct Carcinoma", "Stage II Esophageal Cancer AJCC v7", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage IIA Esophageal Cancer AJCC v7", "Stage IIA Pancreatic Cancer AJCC v6 and v7", "Stage IIB Esophageal Cancer AJCC v7", "Stage IIB Pancreatic Cancer AJCC v6 and v7", "Stage III Colon Cancer AJCC v7", "Stage III Esophageal Cancer AJCC v7", "Stage III Gastric Cancer AJCC v7", "Stage III Liver Cancer", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Rectal Cancer AJCC v7", "Stage III Small Intestinal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Esophageal Cancer AJCC v7", "Stage IIIA Gastric Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIA Small Intestinal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Esophageal Cancer AJCC v7", "Stage IIIB Gastric Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIB Small Intestinal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Esophageal Cancer AJCC v7", "Stage IIIC Gastric Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Stage IV Liver Cancer", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Rectal Cancer AJCC v7", "Stage IV Small Intestinal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Liver Cancer", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Liver Cancer", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ropidoxuridine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-02-01", "completion_date": "2027-03-14", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02381561" }, { "nct_id": "NCT05038254", "title": "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Small Intestinal Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Pancreatic Carcinoma", "Metastatic Rectal Carcinoma", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2021-05-12", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038254" }, { "nct_id": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2024-06-24", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 375, "location_summary": "Little Rock, Arkansas • Anaheim, California • Baldwin Park, California + 286 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203600" }, { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" }, { "nct_id": "NCT00019825", "title": "Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Lung Cancer", "Malignant Mesothelioma", "Metastatic Cancer" ], "interventions": [ { "name": "decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019825" }, { "nct_id": "NCT00030862", "title": "Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-10", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030862" }, { "nct_id": "NCT00281788", "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2003-09", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-03-21", "last_synced_at": "2026-10-14T12:29:07.184Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281788" } ] }